Senores Pharmaceuticals is set to launch its IPO on December 20, 2024, with the closing date scheduled for December 24, 2024. This IPO is a Book Built Issue, with the company aiming to raise approximately ₹[.] crores. This amount includes a fresh issue of ₹500 crores and an offer for sale of up to 21,00,000 equity shares, each with a face value of ₹10.
The price band for Senores Pharmaceuticals IPO is set at ₹[.] to ₹[.] per share. The allocation for retail investors is 10%, while Qualified Institutional Buyers (QIB) will receive 75% and High Net Worth Individuals (HNI) will receive 15%. The IPO is expected to be listed on both the BSE and NSE on December 30, 2024, with the allotment date scheduled for December 26, 2024.
In terms of financial performance, the company reported revenue of ₹217.34 crores in 2024, a significant increase from ₹39.02 crores in 2023. However, the company also reported a loss of ₹32.71 crores in 2024, compared to a profit of ₹8.43 crores in 2023. Despite this, investors are advised to consider applying for the IPO with a long-term perspective.
Senores Pharmaceuticals IPO Details
| IPO Open Date: | December 20, 2024 |
| IPO Close Date: | December 24, 2024 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹[.] to ₹[.] Per Share |
| Issue Size: | Approx ₹[.] Crores |
| Fresh Issue: | Approx ₹500 Crores |
| Offer for Sale: | Approx 21,00,000Equity Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 10% |
| QIB Quota: | Not more than 75% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | NA |
Senores Pharmaceuticals IPO Market Lot
The Senores Pharmaceuticals IPO minimum market lot is [.] shares with ₹[.] application amount. The retail investors can apply up-to 13 lots with [.] shares or ₹[.] amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | – | ₹- |
| Retail Maximum | 13 | – | ₹- |
| S-HNI Minimum | 14 | – | ₹- |
| B-HNI Minimum | 68 | – | ₹- |
Senores Pharmaceuticals IPO Dates
The Senores Pharmaceuticals IPO date is December 20 and the close date is December 24. The Senores Pharmaceuticals IPO allotment will be finalized on December 26 and the IPO listing on December 30.
| IPO Open Date: | December 20, 2024 |
| IPO Close Date: | December 24, 2024 |
| Basis of Allotment: | December 26, 2024 |
| Refunds: | December 27, 2024 |
| Credit to Demat Account: | December 27, 2024 |
| IPO Listing Date: | December 30, 2024 |
Promoters of Senores Pharmaceuticals IPO
The promoters of the company are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot
About Senores Pharmaceuticals IPO
Senores Pharmaceuticals is a leading company specializing in generic medicine, certified by global food and drug authorities. Committed to providing high-quality products, Senores is dedicated to meeting the growing demand in the global healthcare industry. Their current focus is on innovation, production, and manufacturing, with a vision of making healthcare more affordable and accessible, particularly for a variety of products.
Senores Pharmaceuticals offers a dynamic strategy, providing access to a range of high-quality products. They excel in identifying, producing, and distributing specialty, underpenetrated, and complex pharmaceutical products, earning the trust and loyalty of customers. With a strong presence in the US and Canadian markets, Senores has also expanded its reach to 43 countries worldwide.
In addition to generic medicine, Senores Pharmaceuticals manufactures critical care injectables and active pharmaceutical ingredients (APIs), further solidifying their position as a trusted and reliable pharmaceutical company.
Senores Pharmaceuticals IPO Company Financial Report
The company reported whooping revenue of ₹217.34 crores in 2024 against ₹39.02 crore in 2023. But on the other hand the company reported loss of ₹32.71 crores in 2024 against Profit of ₹8.43 crores in 2023. This might b because the company is trying to expand and in that case company has to incur some losses in the beginning.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹14.63 | ₹13.49 | ₹0.99 | ₹59.15 |
| 2023 | ₹39.02 | ₹26.58 | ₹8.43 | ₹131.05 |
| 2024 | ₹217.34 | ₹192.40 | ₹32.71 | ₹621.88 |
| September 2024 | ₹183.35 | ₹153.95 | ₹23.94 | ₹678.08 |
Senores Pharmaceuticals IPO Valuation – FY2024
Check Senores Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 23.60% |
| ROCE: | 11.73% |
| EBITDA Margin: | 20.70% |
| PAT Margin: | 15.25% |
| Debt to equity ratio: | 1.07 |
| Earning Per Share (EPS): | ₹13.67 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 23.60% |
| Net Asset Value (NAV): | ₹66.96 |
Peer Group Comparison
Now, lets look at the peer comparison’s performance over this financial year so that a better understanding will be there at the time of Sensores’ analysis.
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Ajanta Pharma Limited | 64.82 | 34.37 | 23.47% | 281.60 | 4208.71 Cr. |
| Alembic Pharmaceuticals Limited | 31.33 | 34.58 | 13.40% | 245.12 | 6228.63 Cr. |
| Caplin Point Laboratories Limited | 60.79 | 25.23 | 21.69% | 309.03 | 1694.10 Cr. |
| Gland Pharma Limited | 46.90 | 43.73 | 9.26% | 529.65 | 5664.72 Cr. |
| Strides Pharma Science Limited | (7.76) | NA | (4.44%) | 225.43 | 4051.12 Cr. |
Objects of the Issue
- We will be funding our capital expenditure requirements by investing in one of our Subsidiaries, Havix Group, Inc. operating as Aavis Pharmaceuticals (“Havix”), to establish a manufacturing facility for producing sterile injections at our Atlanta Facility.
- Additionally, we will be repaying or prepaying certain borrowings obtained by our Company and Subsidiaries, including Havix, Ratnatris Pharmaceutical Private Limited (“Ratnatris”), and Senores Pharmaceuticals Inc. (“SPI”).
- Furthermore, we will be providing funding for the working capital needs of our Company and Subsidiaries, specifically SPI and Ratnatris.
- Lastly, we plan to use funds for inorganic growth through acquisitions and other strategic initiatives, as well as for general corporate purposes.
Stay tuned for more updates and insights on the stock market! For more insights on investing in the Indian stock market, check out resources like Moneycontrol and NSE India.